Hypoglycemic and hypolipidemic mechanism of organic chromium derived from chelation of Grifola frondosa polysaccharide-chromium (III) and its modulation of intestinal microflora in high fat-diet and STZ-induced diabetic mice
| Autor: | Min Chen, Wen-Li Pan, Xu-Cong Lv, Pingfan Rao, Bin Liu, Li Ni, Jia-Xin Xu, Qing Zhang, Lu Li, Weidong Bai, Yan-Yan Zhang, Yi-Chen Lin, Wei-Ling Guo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
Chromium Male 02 engineering and technology Pharmacology Diet High-Fat Polysaccharide Biochemistry Streptozocin Diabetes Mellitus Experimental Mice 03 medical and health sciences chemistry.chemical_compound Polysaccharides Structural Biology Hyperlipidemia Dietary Carbohydrates medicine Animals Hypoglycemic Agents RNA Messenger Molecular Biology Triglycerides Grifola frondosa Chelating Agents Hypolipidemic Agents 030304 developmental biology chemistry.chemical_classification 0303 health sciences Triglyceride Chemistry Cholesterol Lipid metabolism General Medicine Lipid Metabolism 021001 nanoscience & nanotechnology medicine.disease Gastrointestinal Microbiome Glucose Liver Hyperglycemia Metagenomics Steatosis 0210 nano-technology Grifola |
| Zdroj: | International Journal of Biological Macromolecules. 145:1208-1218 |
| ISSN: | 0141-8130 |
| Popis: | Polysaccharide from Grifola frondosa is an excellent metal-ion chelating agent owing to its distinctive structure and outstanding functional activities. Our previous research has successfully synthesized novel organic chromium derived from the chelation ofG. frondosapolysaccharide-chromium (III) [GFP-Cr(III)]. The purpose of present research was to reveal the hypoglycemic and hypolipidemic mechanism of GFP-Cr(III), and its relationship with the modulation of intestinal microflora. Successful fabrication of GFP-Cr(III) was verified by thermogravimetric analysis (TGA), powder X-ray diffraction (XRD) and 1H NMR spectrum.The hypoglycemic and hypolipidemic effects were examined using type 2 diabetic mice induced by a high-fat diet (HFD) and streptozocin (STZ). Results indicated that GFP-Cr(III) intervention improved abnormal serum biochemical indicators (triglyceride (TG), cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and glucose), inhibited lipid accumulation and steatosis in the liver. Metagenomic analysis revealed that GFP-Cr(III) treatment produced obvious changes on the intestinal microflora in T2DM mice. Thecorrelationnetwork analysis further revealed that the serum and hepatic lipid profiles were positively correlated with Streptococcus and Enterococcus, but negatively correlated with Enterorhabdus, Ruminococcaceae-UCG-011, Coriobacteriaceae and Micrococcaceae. Meanwhile, oral administration with GFP-Cr(III) regulated the mRNA expression related to glucose and lipid metabolism. These results of present study suggest that GFP-Cr(III) could be used as potential functional food ingredients for the amelioration of hyperglycemia and hyperlipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect